Links to Exploration step
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Hippocampal perfusion predicts impending neurodegeneration in REM sleep behavior disorder</title><author><name sortKey="Dang Vu, Thien Thanh" sort="Dang Vu, Thien Thanh" uniqKey="Dang Vu T" first="Thien Thanh" last="Dang-Vu">Thien Thanh Dang-Vu</name></author><author><name sortKey="Gagnon, Jean Francois" sort="Gagnon, Jean Francois" uniqKey="Gagnon J" first="Jean-François" last="Gagnon">Jean-François Gagnon</name></author><author><name sortKey="Vendette, Melanie" sort="Vendette, Melanie" uniqKey="Vendette M" first="Mélanie" last="Vendette">Mélanie Vendette</name></author><author><name sortKey="Soucy, Jean Paul" sort="Soucy, Jean Paul" uniqKey="Soucy J" first="Jean-Paul" last="Soucy">Jean-Paul Soucy</name></author><author><name sortKey="Postuma, Ronald B" sort="Postuma, Ronald B" uniqKey="Postuma R" first="Ronald B." last="Postuma">Ronald B. Postuma</name></author><author><name sortKey="Montplaisir, Jacques" sort="Montplaisir, Jacques" uniqKey="Montplaisir J" first="Jacques" last="Montplaisir">Jacques Montplaisir</name></author></titleStmt><publicationStmt><idno type="wicri:source">PMC</idno><idno type="pmid">23115214</idno><idno type="pmc">3578380</idno><idno type="url">http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3578380</idno><idno type="RBID">PMC:3578380</idno><idno type="doi">10.1212/WNL.0b013e318278b658</idno><date when="2012">2012</date><idno type="wicri:Area/Pmc/Corpus">000635</idno><idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Corpus" wicri:corpus="PMC">000635</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en" level="a" type="main">Hippocampal perfusion predicts impending neurodegeneration in REM sleep behavior disorder</title><author><name sortKey="Dang Vu, Thien Thanh" sort="Dang Vu, Thien Thanh" uniqKey="Dang Vu T" first="Thien Thanh" last="Dang-Vu">Thien Thanh Dang-Vu</name></author><author><name sortKey="Gagnon, Jean Francois" sort="Gagnon, Jean Francois" uniqKey="Gagnon J" first="Jean-François" last="Gagnon">Jean-François Gagnon</name></author><author><name sortKey="Vendette, Melanie" sort="Vendette, Melanie" uniqKey="Vendette M" first="Mélanie" last="Vendette">Mélanie Vendette</name></author><author><name sortKey="Soucy, Jean Paul" sort="Soucy, Jean Paul" uniqKey="Soucy J" first="Jean-Paul" last="Soucy">Jean-Paul Soucy</name></author><author><name sortKey="Postuma, Ronald B" sort="Postuma, Ronald B" uniqKey="Postuma R" first="Ronald B." last="Postuma">Ronald B. Postuma</name></author><author><name sortKey="Montplaisir, Jacques" sort="Montplaisir, Jacques" uniqKey="Montplaisir J" first="Jacques" last="Montplaisir">Jacques Montplaisir</name></author></analytic><series><title level="j">Neurology</title><idno type="ISSN">0028-3878</idno><idno type="eISSN">1526-632X</idno><imprint><date when="2012">2012</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en"><sec><title>Objectives:</title><p>Patients with idiopathic REM sleep behavior disorder (IRBD) are at risk for developing Parkinson disease (PD) and dementia with Lewy bodies (DLB). We aimed to identify functional brain imaging patterns predicting the emergence of PD and DLB in patients with IRBD, using SPECT with <sup>99m</sup>Tc–ethylene cysteinate dimer (ECD).</p></sec><sec><title>Methods:</title><p>Twenty patients with IRBD were scanned at baseline during wakefulness using <sup>99m</sup>Tc-ECD SPECT. After a follow-up of 3 years on average, patients were divided into 2 groups according to whether or not they developed defined neurodegenerative disease (PD, DLB). SPECT data analysis comparing regional cerebral blood flow (rCBF) between groups assessed whether specific brain perfusion patterns were associated with subsequent clinical evolution. Regression analysis between rCBF and clinical markers of neurodegeneration (motor, color vision, olfaction) looked for neural structures involved in this process.</p></sec><sec><title>Results:</title><p>Of the 20 patients with IRBD recruited for this study, 10 converted to PD or DLB during the follow-up. rCBF at baseline was increased in the hippocampus of patients who would later convert compared with those who would not (<italic>p</italic> < 0.05 corrected). Hippocampal perfusion was correlated with motor and color vision scores across all IRBD patients.</p></sec><sec><title>Conclusions:</title><p><sup>99m</sup>Tc-ECD SPECT identifies patients with IRBD at risk for conversion to other neurodegenerative disorders such as PD or DLB; disease progression in IRBD is predicted by abnormal perfusion in the hippocampus at baseline. Perfusion within this structure is correlated with clinical markers of neurodegeneration, further suggesting its involvement in the development of presumed synucleinopathies.</p></sec></div></front></TEI><pmc article-type="research-article"><pmc-comment>The publisher of this article does not allow downloading of the full text in XML form.</pmc-comment>
<front><journal-meta><journal-id journal-id-type="nlm-ta">Neurology</journal-id><journal-id journal-id-type="iso-abbrev">Neurology</journal-id><journal-id journal-id-type="hwp">neurology</journal-id><journal-id journal-id-type="publisher-id">neur</journal-id><journal-id journal-id-type="pmc">neurology</journal-id><journal-id journal-id-type="publisher-id">WNL</journal-id><journal-title-group><journal-title>Neurology</journal-title></journal-title-group><issn pub-type="ppub">0028-3878</issn><issn pub-type="epub">1526-632X</issn><publisher><publisher-name>Lippincott Williams & Wilkins</publisher-name><publisher-loc>Hagerstown, MD</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">23115214</article-id><article-id pub-id-type="pmc">3578380</article-id><article-id pub-id-type="publisher-id">WNL204505</article-id><article-id pub-id-type="doi">10.1212/WNL.0b013e318278b658</article-id><article-id pub-id-type="art-access-id">00005</article-id><article-categories><subj-group subj-group-type="hwp-journal-coll"><subject>28</subject><subject>123</subject><subject>165</subject><subject>248</subject></subj-group><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title>Hippocampal perfusion predicts impending neurodegeneration in REM sleep behavior disorder</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name><surname>Dang-Vu</surname><given-names>Thien Thanh</given-names></name><degrees>MD, PhD</degrees><author-comment content-type="disclosure"><p><list list-type="order"><title>Scientific Advisory Boards:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Gifts:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Funding for Travel or Speaker Honoraria:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Editorial Boards:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Patents:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Publishing Royalties:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Employment, Commercial Entity:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Consultancies:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Speakers' Bureaus:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Other Activities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Clinical Procedures or Imaging Studies:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Research Support, Commercial Entities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Research Support, Government Entities:</title><list-item><p>Funded by the Canadian Institutes of Health Research, the Belgian Fonds National de la Recherche Scientifique, and Wallonie-Bruxelles International.</p></list-item></list></p><p><list list-type="order"><title>Research Support, Academic Entities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Research Support, Foundations and Societies:</title><list-item><p>Funded by the Fonds Léon Frédéricq, the Belgian College of Neuropsychopharmacology and Biological Psychiatry, the European Sleep Research Society, the Belgian American Educational Foundation, the Belgian Neurological Society, and the Horlait-Dapsens Medical Foundation.</p></list-item></list></p><p><list list-type="order"><title>Stock/Stock Options/Board of Directors Compensation:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>License Fee Payments, Technology or Inventions:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Royalty Payments, Technology or Inventions:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Stock/Stock Options, Research Sponsor:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Stock/Stock Options, Medical Equipment & Materials:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Legal Proceedings:</title><list-item><p>NONE</p></list-item></list></p></author-comment></contrib><contrib contrib-type="author"><name><surname>Gagnon</surname><given-names>Jean-François</given-names></name><degrees>PhD</degrees><author-comment content-type="disclosure"><p><list list-type="order"><title>Scientific Advisory Boards:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Gifts:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Funding for Travel or Speaker Honoraria:</title><list-item><p>Movement Disorders Society, Travel/Speaker honoria for annual congress, Toronto, Canada, 2011; RBD Study Group, Travel/Speaker honoria for annual symposium, Otsu, Japan, 2011.</p></list-item></list></p><p><list list-type="order"><title>Editorial Boards:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Patents:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Publishing Royalties:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Employment, Commercial Entity:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Consultancies:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Speakers' Bureaus:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Other Activities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Clinical Procedures or Imaging Studies:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Research Support, Commercial Entities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Research Support, Government Entities:</title><list-item><p>Dr. Gagnon receives research support from the Canadian Institutes of Health Research [MOP-84482 (PI, 2007-2012), MOP-62955 (Co-PI, 2008-2013), MOP-191058 (Co-Inv, 2009-2014) and MOP-93802 (Co-PI, 2010-2015)] and Fonds de Recherche du Québec - Santé [11834 (PI, 2007-2010)].</p></list-item></list></p><p><list list-type="order"><title>Research Support, Academic Entities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Research Support, Foundations and Societies:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Stock/Stock Options/Board of Directors Compensation:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>License Fee Payments, Technology or Inventions:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Royalty Payments, Technology or Inventions:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Stock/Stock Options, Research Sponsor:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Stock/Stock Options, Medical Equipment & Materials:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Legal Proceedings:</title><list-item><p>NONE</p></list-item></list></p></author-comment></contrib><contrib contrib-type="author"><name><surname>Vendette</surname><given-names>Mélanie</given-names></name><degrees>MSc</degrees><author-comment content-type="disclosure"><p><list list-type="order"><title>Scientific Advisory Boards:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Gifts:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Funding for Travel or Speaker Honoraria:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Editorial Boards:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Patents:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Publishing Royalties:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Employment, Commercial Entity:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Consultancies:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Speakers' Bureaus:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Other Activities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Clinical Procedures or Imaging Studies:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Research Support, Commercial Entities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Research Support, Government Entities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Research Support, Academic Entities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Research Support, Foundations and Societies:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Stock/Stock Options/Board of Directors Compensation:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>License Fee Payments, Technology or Inventions:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Royalty Payments, Technology or Inventions:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Stock/Stock Options, Research Sponsor:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Stock/Stock Options, Medical Equipment & Materials:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Legal Proceedings:</title><list-item><p>NONE</p></list-item></list></p></author-comment></contrib><contrib contrib-type="author"><name><surname>Soucy</surname><given-names>Jean-Paul</given-names></name><degrees>MD, MSc</degrees><author-comment content-type="disclosure"><p><list list-type="order"><title>Scientific Advisory Boards:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Gifts:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Funding for Travel or Speaker Honoraria:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Editorial Boards:</title><list-item><p>Member, Editorial Board, Advances in Alzheimer's Disease,2012 -</p></list-item></list></p><p><list list-type="order"><title>Patents:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Publishing Royalties:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Employment, Commercial Entity:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Consultancies:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Speakers' Bureaus:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Other Activities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Clinical Procedures or Imaging Studies:</title><list-item><p>I practice Nuclear Medicine at both the Montreal, University Medical Centre and Montreal Neurological, Hospital, and I report both SPECT rCBF studies and PET FDG, brain studies as a practitioner.</p></list-item></list></p><p><list list-type="order"><title>Research Support, Commercial Entities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Research Support, Government Entities:</title><list-item><p>24. Beta-cell imaging with 18F-labeled, glibenclamide-glucose conjugates by positron emission, tomography. CIHR 97970; SCHIRRMACHER, R, SOUCY, JP;, $79,462/année x 3 ans (2010), 25. Sleep and mild cognitive impairment. CIHR MOP-102631. MONTPLAISIR J, GAGNON JF, GOSSELIN N, MONCHY O, SOUCY JP. $169,465/année X 5 ans (2010)26. Anatomobehavioral validation of the [18F]fluoroethoxybenzovesamicol, as a PET radiotracer for the diagnosis of Alzheimer's disease. CIHR. Co-PI: BÉDARD, MA, SOUCY JP, ROSA P. Collaborators : DESCARRIES L, MESHAWAR N. $50 000.00 X 1 an (2010), 27. Development of an automated blood counter for quantitative molecular imaging applications. Després, Philippe (IP). CO-APPLICANT(S): Soucy, Jean-Paul; Rosa, Neto, Pedro; Hamel, Louis-André. Projets de recherche, concertée sur la santé (PRCS), programme conjoint CRSNG et, IRSC. Projet # 1004158. 2010: $73000, 2011: $110300, 2012: $61800, 28. In vivo quantification of glutamatergic abnormalities, in patients with Alzheimer's disease. Rosa-Neto, Pedro, (IP); Co-applicants: Gauthier, Serge; Soucy, Jean-Paul. IRSC, demande # 245908, comité BCA. $196,180/année X 4, ans (2011-2014), 29. The neuro-circuitry of terror: High resolution SPECT, imaging of REM sleep in PTSD and Nightmare Disorder. IPs: Nielsen, Torre; Soucy, Jean-Paul. Co-applicant: Montplaisir, Jacques. CIHR MOP-115125. $135 550/année X 5, ans (2011-2015) 30. Anomia in Alzheimer's disease : Untangling semantic, components and delivering therapy with rTMS. Chertkow, Howard, Soucy Jean-Paul, Thiel Alexander. CIHR 259005. $153 303.00/year, 2012-2015, 31. Obstructive sleep apnea and mild cognitive impairment. N Gosselin , J. Y. Montplaisir, L. De Beaumont, J. Gagnon, S. Gauthier, J. P. Soucy. CIHR 272199. $157,816/année, 2012-2016</p></list-item></list></p><p><list list-type="order"><title>Research Support, Academic Entities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Research Support, Foundations and Societies:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Stock/Stock Options/Board of Directors Compensation:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>License Fee Payments, Technology or Inventions:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Royalty Payments, Technology or Inventions:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Stock/Stock Options, Research Sponsor:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Stock/Stock Options, Medical Equipment & Materials:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Legal Proceedings:</title><list-item><p>NONE</p></list-item></list></p></author-comment></contrib><contrib contrib-type="author"><name><surname>Postuma</surname><given-names>Ronald B.</given-names></name><degrees>MD</degrees><author-comment content-type="disclosure"><p><list list-type="order"><title>Scientific Advisory Boards:</title><list-item><p>(1) Teva Neurosciences, Panel Member, 2008</p></list-item></list></p><p><list list-type="order"><title>Gifts:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Funding for Travel or Speaker Honoraria:</title><list-item><p>(1) Allergan, 2011; (2) Teva Neurosciences, 2011, Novartis 2012</p></list-item></list></p><p><list list-type="order"><title>Editorial Boards:</title><list-item><p>(1) Editorial Board, Movement Disorders Journal; (2) Editorial Board, Journal of Caffeine Research</p></list-item></list></p><p><list list-type="order"><title>Patents:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Publishing Royalties:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Employment, Commercial Entity:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Consultancies:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Speakers' Bureaus:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Other Activities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Clinical Procedures or Imaging Studies:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Research Support, Commercial Entities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Research Support, Government Entities:</title><list-item><p>(1) Operating Grant - Canadian Institute of Health Research/Parkinson Society of Canada, grant number 201317, Principal Investigator (10/2009 - 10/2011); (2) Operating Grant - Canadian Institute of Health Research, grant number 192205, co-Principal Investigator (07/2009 - 06/2010); 3. Operating Grant - Canadian Institute of Health Research, grant number 166206 Co-investigator (07/2007 to 06/2012); (4) An Emerging Team in Mobility in Aging, Operating Grant - Canadian Institute of Health Research, Co-investigator (01/2009 - 12/1013); (4) Fonds de Recherche de la Sante Quebec, grant number 9965, Principal Investigator (2006-2009)</p></list-item></list></p><p><list list-type="order"><title>Research Support, Academic Entities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Research Support, Foundations and Societies:</title><list-item><p>(1) Operating Grant - Weston Foundation, Prinicipal Investigator (01/2009 - 01/2011); (2) Operating grant - Drummond Foundation, Principal Investigator (01/2008 - 04/2009)</p></list-item></list></p><p><list list-type="order"><title>Stock/Stock Options/Board of Directors Compensation:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>License Fee Payments, Technology or Inventions:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Royalty Payments, Technology or Inventions:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Stock/Stock Options, Research Sponsor:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Stock/Stock Options, Medical Equipment & Materials:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Legal Proceedings:</title><list-item><p>NONE</p></list-item></list></p></author-comment></contrib><contrib contrib-type="author" corresp="yes"><name><surname>Montplaisir</surname><given-names>Jacques</given-names></name><degrees>MD, PhD</degrees><author-comment content-type="disclosure"><p><list list-type="order"><title>Scientific Advisory Boards:</title><list-item><p>Servier, advisor, 2009; Merck, advisor, 2009-2010 Sanofi-Aventis, 2009-2011; Valeant Pharmaceutical,2011-2012; GSK Pharma 2011-2012</p></list-item></list></p><p><list list-type="order"><title>Gifts:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Funding for Travel or Speaker Honoraria:</title><list-item><p>Valeant Pharmaceutical, Speaker 2010 and 2011; Otsuka Pharmaceutical, Speaker, Japan 2011</p></list-item></list></p><p><list list-type="order"><title>Editorial Boards:</title><list-item><p>(1) Associate editor: Sleep Medicine; (2) Associate editor: Sleep Medicine Reviews</p></list-item></list></p><p><list list-type="order"><title>Patents:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Publishing Royalties:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Employment, Commercial Entity:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Consultancies:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Speakers' Bureaus:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Other Activities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Clinical Procedures or Imaging Studies:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Research Support, Commercial Entities:</title><list-item><p>Merck 2010 - Unrelated to the study, GlaxoSmithKline 2011 - Unrelated to the study</p></list-item></list></p><p><list list-type="order"><title>Research Support, Government Entities:</title><list-item><p>PI: CIHR - MOP-62955 - 2008-2013; PI: CIHR - MOP-106692 - 2011-2015, PI: CIHR- MOP- 102631 - 2010-2015, Co-I: CIHR - MOP- 97825 - 2011-2016; Co-I: CIHR - MOP-115125 - 2012-2017; Co-PI: CIHR - MOP 173519 - 2007-2012, Co-I: CIHR - MOP 64221 - 2008-2012</p></list-item></list></p><p><list list-type="order"><title>Research Support, Academic Entities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Research Support, Foundations and Societies:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Stock/Stock Options/Board of Directors Compensation:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>License Fee Payments, Technology or Inventions:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Royalty Payments, Technology or Inventions:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Stock/Stock Options, Research Sponsor:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Stock/Stock Options, Medical Equipment & Materials:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Legal Proceedings:</title><list-item><p>NONE</p></list-item></list></p></author-comment></contrib></contrib-group><aff>From the Center for Advanced Research in Sleep Medicine (T.T.D.-V., J.-F.G., M.V., R.B.P., J.M.), Hôpital du Sacré-Cœur de Montréal; Department of Exercise Science and Center for Studies in Behavioral Neurobiology (T.T.D.-V.), Concordia University, Montréal, Canada; Cyclotron Research Centre (T.T.D.-V.), University of Liege; Department of Neurology (T.T.D.-V.), Centre Hospitalier Universitaire de Liège, Belgium; Department of Psychology (J.-F.G.), Université du Québec à Montréal; Montreal Neurological Institute (P.S.), McGill University, Montréal; Department of Nuclear Medicine (J.P.-S.), Centre Hospitalier de l’Université de Montréal; Department of Neurology (R.B.P.), Montreal General Hospital; and Department of Psychiatry (J.M.), University of Montreal, Canada.</aff><author-notes><corresp>Correspondence & reprint requests to Dr. Dang-Vu, <email>tt.dangvu@concordia.ca</email> or Dr. Montplaisir, <email>jy.montplaisir@umontreal.ca</email></corresp><fn fn-type="financial-disclosure"><p><italic>Study funding:</italic> Supported by the <funding-source>Canadian Institutes of Health Research</funding-source> and by the <funding-source>Fonds de recherche du Québec–Santé</funding-source>.</p></fn><fn fn-type="financial-disclosure"><p>Go to Neurology.org for full disclosures. Disclosures deemed relevant by the authors, if any, are provided at the end of this article.</p></fn></author-notes><pub-date pub-type="ppub"><day>11</day><month>12</month><year>2012</year></pub-date><pub-date pub-type="pmc-release"><day>11</day><month>6</month><year>2013</year></pub-date><pmc-comment> PMC Release delay is 6 months and 0 days and was based on the
<volume>79</volume><issue>24</issue><fpage>2302</fpage><lpage>2306</lpage><history><date date-type="received"><day>25</day><month>4</month><year>2012</year></date><date date-type="accepted"><day>27</day><month>7</month><year>2012</year></date></history><permissions><copyright-statement>© 2012 American Academy of Neurology</copyright-statement><copyright-year>2012</copyright-year><copyright-holder>American Academy of Neurology</copyright-holder></permissions><self-uri xlink:title="pdf" xlink:type="simple" xlink:href="WNL204505.pdf"></self-uri><abstract><sec><title>Objectives:</title><p>Patients with idiopathic REM sleep behavior disorder (IRBD) are at risk for developing Parkinson disease (PD) and dementia with Lewy bodies (DLB). We aimed to identify functional brain imaging patterns predicting the emergence of PD and DLB in patients with IRBD, using SPECT with <sup>99m</sup>Tc–ethylene cysteinate dimer (ECD).</p></sec><sec><title>Methods:</title><p>Twenty patients with IRBD were scanned at baseline during wakefulness using <sup>99m</sup>Tc-ECD SPECT. After a follow-up of 3 years on average, patients were divided into 2 groups according to whether or not they developed defined neurodegenerative disease (PD, DLB). SPECT data analysis comparing regional cerebral blood flow (rCBF) between groups assessed whether specific brain perfusion patterns were associated with subsequent clinical evolution. Regression analysis between rCBF and clinical markers of neurodegeneration (motor, color vision, olfaction) looked for neural structures involved in this process.</p></sec><sec><title>Results:</title><p>Of the 20 patients with IRBD recruited for this study, 10 converted to PD or DLB during the follow-up. rCBF at baseline was increased in the hippocampus of patients who would later convert compared with those who would not (<italic>p</italic> < 0.05 corrected). Hippocampal perfusion was correlated with motor and color vision scores across all IRBD patients.</p></sec><sec><title>Conclusions:</title><p><sup>99m</sup>Tc-ECD SPECT identifies patients with IRBD at risk for conversion to other neurodegenerative disorders such as PD or DLB; disease progression in IRBD is predicted by abnormal perfusion in the hippocampus at baseline. Perfusion within this structure is correlated with clinical markers of neurodegeneration, further suggesting its involvement in the development of presumed synucleinopathies.</p></sec></abstract></article-meta></front></pmc></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Canada/explor/ParkinsonCanadaV1/Data/Pmc/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 0006350 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Pmc/Corpus/biblio.hfd -nk 0006350 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Canada
|area= ParkinsonCanadaV1
|flux= Pmc
|étape= Corpus
|type= RBID
|clé=
|texte=
}}
| This area was generated with Dilib version V0.6.29. |  |